10-Q: Centessa Pharmaceuticals Reports Q1 2025 Financial Results and Provides Business Update

Centessa Pharmaceuticals announces its Q1 2025 financial results, highlighting a license agreement with Genmab and progress in its orexin agonist program.

Summary

• Centessa Pharmaceuticals reported a net loss of $26.1 million for the three months ended March 31, 2025.
• The company's cash, cash equivalents, and investments totaled $424.9 million as of March 31, 2025.
• A license agreement with Genmab A/S was signed, providing Centessa with a $15.0 million upfront payment.
• The company sold 372,538 ordinary shares under the ATM Program, resulting in net proceeds of $6.1 million.
• The Phase 2a CRYSTAL-1 clinical study of ORX750 in participants with NT1, NT2, and IH was initiated.
• First-in-human studies of ORX142 are planned, with clinical data expected in acutely sleep-deprived healthy volunteers in 2025.
• Clinical development of LB101 was discontinued, and data are informing ongoing preclinical work.
• The company expects its existing cash, cash equivalents and investments will be sufficient to fund its expected operating expenses and capital expenditure requirements for at least the next twelve months.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. The company has a solid cash position and a new licensing agreement, but it is still operating at a loss and has discontinued a clinical program. The sentiment is neutral to slightly positive.

Positives

• The license agreement with Genmab A/S provides a non-refundable upfront payment of $15.0 million and potential future milestones and royalties.
• The initiation of the Phase 2a CRYSTAL-1 clinical study of ORX750 represents progress in the orexin agonist program.
• The company has access to up to an additional $40.0 million of loan proceeds in an additional tranche which is available during the period commencing on the date of the occurrence of the Clinical Milestone through the earlier of: (i) 90 days following the Clinical Milestone and (ii) June 30, 2028.
• The company expects its existing cash, cash equivalents and investments will be sufficient to fund its expected operating expenses and capital expenditure requirements for at least the next twelve months.

Negatives

• The company reported a net loss of $26.1 million for Q1 2025.
• Clinical development of LB101 was discontinued.

Risks

• The company is subject to risks common to other life science companies in various stages of development including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with government regulations in the markets in which the Company is seeking approvals, including U.S. Food and Drug Administration (FDA) regulations.
• The company may not be successful in its efforts to use its differentiated asset-centric approach to drug discovery and development to build a pipeline of product candidates with commercial value.
• A single or limited number of programs, developmental assets or product candidates may comprise a large proportion of the company's value.
• The company will need substantial additional funds to advance development of its product candidates, and it cannot guarantee that it will have sufficient funds available in the future to develop and commercialize its current or future product candidates.
• The company's loan facility and payment obligations under the Loan and Security Agreement with Oxford Finance contain operating and financial covenants that restrict its business and financing activities, are subject to acceleration in specified circumstances and may adversely affect its financial position or results of operations and its ability to raise additional capital which in turn may increase its vulnerability to adverse regulatory developments or economic or business downturns or which may result in Oxford Finance taking possession of its assets and disposing of any collateral.
• The company's product candidates are in various stages of development, including several in discovery and preclinical stages, and may fail in development or suffer delays that materially adversely affect their commercial viability and the company may fail to differentiate its molecules, including ORX750, ORX142, ORX489 and other orexin agonist molecules, LockBody molecules and/or the LockBody technology platform from other available treatment options including other molecules in development.
• The company may not be successful in its efforts to identify, discover, in-license or otherwise acquire additional product candidates and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success.
• Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
• The company may encounter substantial delays or challenges in the initiation, conduct or completion of its clinical trials, and the results of clinical development are uncertain.
• Even if the company completes the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent it from obtaining approvals for the commercialization of its product candidates.
• The company may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to develop and/or commercialize its product candidates.
• The company relies, and expects to continue to rely, on third parties to conduct its preclinical studies and clinical trials and if these third parties perform in an unsatisfactory manner, its business could be substantially harmed.
• Preclinical and clinical development is a long, expensive and uncertain process, and the company may terminate one or more of its current preclinical and/or clinical development programs.
• The company could experience manufacturing problems that result in delays or other material disruptions in its development or commercialization of its programs or otherwise harm its business.
• Business interruptions resulting from the Russia-Ukraine war, the Middle East conflict(s), tensions in U.S. China relations, or similar geo-political conflicts could cause a disruption to its business activities including the development of its product candidates and the conduct of clinical trials thereby adversely impacting its business.
• If the company is unable to obtain and maintain sufficient patent and other intellectual property protection for its product candidates and technology or other product candidates that may be identified, or if the scope of the intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize product candidates similar or identical to the product candidates, and its ability to successfully commercialize the product candidates and other product candidates that it may pursue may be impaired.
• The patent protection the company obtains for its product candidates and technology may be challenged or not sufficient enough to provide it with any competitive advantage.
• A number of the company's programs and associated product candidates are heavily dependent on licensed intellectual property. If the company were to lose its rights to licensed intellectual property, it may not be able to continue developing or commercializing its product candidates, if approved. If the company breaches any of the agreements under which it licenses the use, development and commercialization rights to its product candidates or technology from third parties or, in certain cases, it fails to meet certain development deadlines, it could lose license rights that are important to its business.
• The company has never commercialized a product candidate and it may lack the necessary expertise, personnel and resources to successfully commercialize any of its products that receive regulatory approval on its own or together with collaborators.
• The company's international operations may expose it to business, regulatory, legal, political, operational, financial, pricing and reimbursement risks associated with doing business across multiple jurisdictions outside of the United States.
• The company is an emerging growth company and a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make its ADSs less attractive to investors.
• The company previously had material weaknesses in its internal control systems over financial reporting, which have been remediated. The company may identify new material weaknesses in the future that may cause it to fail to meet its reporting obligations or result in material misstatements in its financial statements. If the company fails to remediate any new material weaknesses, it may not be able to report its financial results accurately or to prevent fraud.
• If the company fails to develop or maintain an effective system of disclosure controls and internal control over financial reporting, its ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
• Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.
• While the company does not believe it was a passive foreign investment company (PFIC) in 2024, there is uncertainty a s to whether it is or will be a PFIC in the past or in the future. If the company is a PFIC, there could be material adverse U.S. federal income tax consequences to U.S. holders.

Future Outlook

The company expects its existing cash, cash equivalents and investments as of March 31, 2025 of $424.9 million will be sufficient to fund its expected operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these unaudited interim consolidated financial statements.

Industry Context

Centessa's focus on orexin receptor 2 (OX2R) agonists aligns with growing interest in treatments for sleep disorders and neurological conditions. The license agreement with Genmab reflects a trend of collaboration in the biotechnology industry to leverage innovative technology platforms.

Comparison to Industry Standards

• It is difficult to compare Centessa's results directly to industry standards due to its unique asset-centric approach and diversified pipeline.
• However, the company's cash runway into mid-2027 is comparable to other clinical-stage biotech companies of similar size.
• The net loss reported is within the expected range for a company investing heavily in research and development.
• The Genmab license agreement is a positive development, but the long-term financial impact will depend on the success of Genmab's research and development efforts.
• Companies like Jazz Pharmaceuticals and Takeda are also developing treatments for sleep disorders, representing potential competitors in the orexin agonist space.
• The discontinuation of LB101 highlights the inherent risks in drug development, which is a common occurrence in the industry.

Stakeholder Impact

• Shareholders: The financial results and business updates provide information for investment decisions.
• Employees: The company's progress and financial stability impact job security and opportunities.
• Patients: The clinical development programs aim to deliver new treatments for various diseases.
• Partners: The license agreement with Genmab and other collaborations create opportunities for joint development and commercialization.

Next Steps

• Continue the Phase 2a CRYSTAL-1 clinical study of ORX750.
• Initiate first-in-human studies of ORX142.
• Advance ORX489 into IND-enabling activities.
• Continue preclinical work focused on identifying new targets and effectors for the LockBody platform.

Key Dates

Keywords

Centessa Pharmaceuticals, financial results, Q1 2025, ORX750, ORX142, Genmab, license agreement, clinical trials, ATM program, LockBody, pharmaceuticals, biotechnology